Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 4/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532421 | 0.91 | SCD5 (0.39) | DRD2SCD5SPRCACNA1HUSP2 | |
| SCHEMBL2423294 | 0.85 | RORC (0.41) | SCD5 | |
| SCHEMBL2526910 | 0.81 | DRD2 (0.40) | DRD2SCD5KDM4EALDH1A1 | |
| SCHEMBL2534867 | 0.80 | SCD5 (0.39) | DRD2SCD5USP2CYP3A4CYP2C19 | |
| SCHEMBL2531711 | 0.79 | DRD2 (0.43) | DRD2FFAR4SPRMETAP2PROKR1 | |
| SCHEMBL2426214 | 0.77 | DRD2 (0.39) | DRD2FFAR4METAP2 | |
| SCHEMBL9186072 | 0.77 | ESR1 (0.36) | DRD2SCD5SPRUSP2CYP3A4 | |
| SCHEMBL3384895 | 0.76 | DRD2 (0.47) | DRD2FFAR4METAP2KDM4ECYP3A4 | |
| SCHEMBL23706066 | 0.76 | SCD5 (0.52) | SCD5USP2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL2428683 | 0.75 | RORC (0.43) | SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673962-B2 | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2014-03-18 | — | — | US | disclosed |
| EP-2367787-B1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2013-01-09 | — | — | EP | disclosed |
| US-20110257241-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | disclosed |
| US-20110257242-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257242-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, COMT, SLC6A3 | DRD2 12/4885FFAR4 1856/4885SCD5 3094/4885 |
| US-20110257241-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, COMT, SLC6A3 | DRD2 14/4885FFAR4 1795/4885SCD5 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.